drugset / Trial / NCT06409429
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX for postoperative adjuvant treatment of pancreatic cancer.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2027-05-30
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 600 mg | — |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |